Intratumoral delivery of FLT3L with CXCR3/CCR5 ligands promotes XCR1&lt;sup&gt;+&lt;/sup&gt; cDC1 infiltration and activates anti-tumor immunity. Here, XCR1 is linked to neoplasm.